
Oruka Therapeutics, Inc.: updates and filings
Price
$95.81
November 20, 2026Market cap $6.5B
What Ploutos Investor adds for Oruka Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 11 fiscal years, from 2014
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Aug 10, 2026next Feb 4, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
August 2026
April 2026
December 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 26, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 27, 2026FilingFormEFFECT
- Aug 24, 2026Officer or director changeForm8-K
- Aug 21, 2026Shelf registration for future offeringsFormS-3
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 12, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 10, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 10, 2026Results of operationsForm8-K
- Jul 1, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jun 4, 2026Shareholder voteForm8-K
- Jun 1, 2026Other material eventsForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 4, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Apr 30, 2026Results of operations, other material eventsForm8-K
- Apr 27, 2026Regulation FD disclosure, other material eventsForm8-K
- Apr 17, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 17, 2026Additional annual meeting materialFormDEFA14A
- Apr 17, 2026Annual meeting proxy statementFormDEF 14A
- Apr 10, 2026FilingFormEFFECT
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 26, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 27, 2026 | EFFECT | Filing | Document |
| Aug 24, 2026 | 8-K | Officer or director change | Document |
| Aug 21, 2026 | S-3 | Shelf registration for future offerings | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 12, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 10, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 10, 2026 | 8-K | Results of operations | Document |
| Jul 1, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jun 4, 2026 | 8-K | Shareholder vote | Document |
| Jun 1, 2026 | 8-K | Other material events | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 4, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Apr 30, 2026 | 8-K | Results of operations, other material events | Document |
| Apr 27, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Apr 17, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 17, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 17, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 10, 2026 | EFFECT | Filing | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since Jun 12, 1997: every report, 8-K, meeting and letter. Of its other filings (1,012 in all), the newest. Of its note and share prospectuses (424B, FWP), the newest 40 of 93.
The full analysis
What do Oruka Therapeutics's filings show?
The filings are where every one of Oruka Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.